Galectin Therapeutics Inc. (GALT) Stock Price
GALTStock
$3.99−5.37%52W
Market Cap$402.39M
P/E—
PEG Ratio-36.15
Div yield—
Beta0.38
GALT Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)26.34%
Price vs S&P 500 (4W)11.40%
PEG Ratio-36.15
VGM Score74.02
GALT Earnings Surprise History
Q2 25-0.12est. -0.16
Q3 25-0.13est. -0.11
Q4 25-0.08est. -0.10
Q1 26-0.08est. -0.06
Q2 26-0.14est. -0.09
GALT Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GALTGalectin Therapeutics Inc. | — | — | B | $3.99 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Galectin Therapeutics Inc.
Galectin Therapeutics is a clinical-stage biopharmaceutical company developing belapectin, a galectin-3 inhibitor targeting liver fibrosis, cancer, and related diseases. Preclinical studies have demonstrated belapectin's potential to reverse liver fibrosis and cirrhosis, addressing significant unmet medical needs.